BMC neurology · 2015
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer's disease.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Silajdžić Edina, Björkqvist Maria, Hansson Oskar
Аннотация
BACKGROUND: Phosphorylcholine is one of the major epitopes of oxidised low density lipoprotein. Low levels of IgM antibodies against phosphorylcholine (anti-PC) are associated with development of myocardial infarction and stroke. It has been shown that patients with Alzheimer's disease and other dementias have significantly lower serum anti-PC levels compared to controls, suggesting that low levels of atheroprotective anti-PC may play a role in AD and dementia.
METHODS: We quantified levels of anti-PC levels using an ELISA in plasma from 176 controls, 125 patients with Alzheimer's disease, 19 patients with vascular dementia and 63 patients with other dementias.
RESULTS: We observed similar plasma anti-PC levels in controls, patients with Alzheimer's disease, and other dementias.
CONCLUSIONS: Our data suggests that anti-PC is not useful as a biomarker for Alzheimer's disease.
METHODS: We quantified levels of anti-PC levels using an ELISA in plasma from 176 controls, 125 patients with Alzheimer's disease, 19 patients with vascular dementia and 63 patients with other dementias.
RESULTS: We observed similar plasma anti-PC levels in controls, patients with Alzheimer's disease, and other dementias.
CONCLUSIONS: Our data suggests that anti-PC is not useful as a biomarker for Alzheimer's disease.